Abstract:Taxol (paclitaxel) response is profiled against a panel of clinical missence mutations in β‐tubulin at molecular and cellular levels, aiming to understanding of molecular mechanism and biological implication underlying drug resistance and sensitivity conferring from tubulin mutations. The Paclitaxel‐resistant mutations can be classified into three types, namely nonbonded interaction broken due to mutation, steric hindrance caused by mutation, and conformational change upon mutation. Taxol (paclitaxel) is the first approved microtubule‐stabilizing agent (MSA) by binding stoichiometrically to tubulin, which is considered to be one of the most significant advances in first‐line chemotherapy against diverse tumors. However, a large number of residue missence mutations harboring in the tubulin have been observed to cause acquired drug resistance, largely limiting the clinical application of Taxol and its analogs in chemotherapy. A systematic investigation of the intermolecular interactions between the Taxol and various tubulin mutants would help to establish a comprehensive picture of drug response to tubulin mutations in clinical treatment of cancer, and to design new MSA agents with high potency and selectivity to overcome drug resistance. In this study, we described an integration of in silico analysis and in vitro assay (iSiV) to profile Taxol against a panel of 149 clinically observed, cancer‐associated missence mutations in β‐tubulin at molecular and cellular levels, aiming to a systematic understanding of molecular mechanism and biological implication underlying drug resistance and sensitivity conferring from tubulin mutations. It is revealed that the Taxol‐resistant mutations can be classified into three types: (I) nonbonded interaction broken due to mutation, (II) steric hindrance caused by mutation, and (III) conformational change upon mutation. In addition, we identified three new Taxol‐resistant mutations (C239Y, T274I, and R320P) that can largely reduce the binding affinity of Taxol to tubulin at molecular level, in which the T274I and R320P were observed to considerably impair the antitumor activity of Taxol at cellular level. Moreover, a novel drug‐susceptible mutation (M363T) was also identified, which improves Taxol affinity by 2.6‐fold and decreases Taxol antitumor EC50 values from 29.4 to 18.7 μM.

Thiostrepton induces spindle abnormalities and enhances Taxol cytotoxicity in MDA-MB-231 cells

Thiostrepton Selectively Targets Breast Cancer Cells Through Inhibition of Forkhead Box M1 Expression

SB-T-121205, a Next-Generation Taxane, Enhances Apoptosis and Inhibits Migration/invasion in MCF-7/PTX Cells

Molecular Mechanism of Forkhead Box M1 Inhibition by Thiostrepton in Breast Cancer Cells.

Role of FOXM1 Expression Inbibition Regulated by Thiostrepton in the Proliferation and Apoptosis of Lung Cancer Cells

Inhibition of sonic hedgehog signaling pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-stem-like population and sphere-forming capacity in triple-negative breast cancer

The Taxane-Enhancer Sta-4783 Induces Hsp70 Expression And Apoptosis Via An Oxidative Stress Mechanism

Sensitizing the Therapeutic Efficacy of Taxol with Shikonin in Human Breast Cancer Cells

Thiostrepton and Mir-216B Synergistically Promote Osteosarcoma Cell Cytotoxicity and Apoptosis by Targeting FoxM1

Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents

Inhibition of FOXM1 by Thiostrepton Sensitizes Medulloblastoma to the Effects of Chemotherapy.

Role of inhibition of transcription factor FOXM1 expression by Thiostrepton in the proliferation and AG1478 sensitivity of non-small cell lung cancer cell

Liposomal Thiostrepton Formulation and Its Effect on Breast Cancer Growth Inhibition

Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy.

Systematic profiling of Taxol resistance and sensitivity to tubulin missence mutations at molecular and cellular levels

Thiostrepton as a Potential Therapeutic Agent for Hepatocellular Carcinoma

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer

10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling

Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells.

Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-α